宫颈癌是女性第二常见肿瘤，世界第五恶性肿瘤，我国妇科首位恶性肿瘤，并且预后极差[1]。传统治疗有手术或放疗，但近年报告新辅助化疗能缩小肿瘤体积、清除或抑制亚临床转移灶、提高后续疗效，正受到日益关注。本文综述新辅助化疗的基本概念、在宫颈癌治疗中的作用、与手术和放疗的关系、以及影响其疗效的诸多因素。
Cervical cancer is the second commonest cancer in women, the fifth commonest malignancies in worldwide, the first cancer of department of gynecology in China and the prognosis is very bad[1]. The standard treatment was usually radiotherapy or radical hysterectomy, recently more and more reviews found giving chemotherapy before radical surgery(neoadjuvant chemotherapy) might shrink the tumour,remove or suppress subclinical metastasis and improve the follow-up effect.It gets more and more attention.The article stated the definition of Neoadjuvant chemotherapy,the use in treatment of cervical cancer,the relationship with the surgery and radiotherapy and the factors affecting Neoadjuvant chemotherapy.
[1]V.Kesic.Management of cervical cervical cancer.European Journal of Surgical [J].Oncology,2006,32(8):832-837.
[2] Oliver Z,Kaled M,Yukio S,et al.Treatment patterns of FIGO Stage IB2 cervical cancer:a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy[J].Gynecol Oncol,2008,111(2):265-270.
[3] 吴良芝,李春梅,刘雯雯,等.局部晚期宫颈癌新辅助化疗分子疗效研究[J]. 中国实验诊断学,2010,14(5):738-741.
[4] RosePG.Locally advanced cervical cancer [J].Curr Opin Obstet Gynecol,2001,13(1):65-70.
[5] Rob L,Halaska M,Robova H.Nerve sparing and individually tailored surgery for cervical cancer [J].Lancet Oncol,2010,11(3):292-301.
[6] HornLC,Fischer U,Raptis G,et al.Hentschel.Tumor size is of prognostic value in surgically treated FIGO stage Ⅱcervical cancer [J].Gynecol Oncol,2007,107(2 ):310-315.
[7] 严冬梅,宫颈癌术前新辅助化疗47例疗效观察[J].中华实用诊断与治疗杂志,2010,24(2):192-194.
[8] Duenas-Gonzalez A,Cetina-Perez L,Onate-Ocana LF,et a1.Multimodal treatment of locally advanced cervical cancer[J].Arch Med Res,2005,36(2):129-135.
[9] 王光,黄玲惠等,宫颈癌新辅助化疗疗效分析[J].中国妇产科临床杂志,2013,14(1):20-22.
[10] Kim HS,Sardi JE,Katsumata N.Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer:An international collaborative meta-analysis,European Journal of Surgical Oncology,2013,39(2):115-124.
[11] Park DC,Suh MJ,Yeo SG.Neoadjuvant paclitaxel and cisplatin in uterine cervical cancer:long-term results[J].Int J Gynecol Cancer,2009,19(5):943-947.
[12] 李超,局部晚期宫颈癌新辅助化疗疗效观察[J].肿瘤基础与临床,2011,24(4):334-335.
[13] Vizza E,Pellegrino A,Milani R,et al.Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in locally advanced stage IB2-IIB cervical cancer patients after neoadjuvant chemotherapy [J].Eur J Surg Oncol,2010,37(4):364-369.
[14] Rose PG,Ali S,Watkins E,et al.Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin,cisplatin-based combination chemotherapy,or hydroxyurea during pelvic irradiation for locally advanced cervical cancer:a Gynecologic Oncology Group Study[J].J Clin Oncol,2007,25(19):2804-2810.
[15] Monk BJ,Tewari KS,Koh W-J.Multimodality therapy for locally advanced cervical carcinoma:state of the art and future directions[J].J Clin Oncol,2007,25:2952-2965.
[16] 刘月玲,同步放化疗对中晚期宫颈癌患者的临床治疗效果[J].中国实用医药,2012,7(2),53-54.
[17] Eifel PJ.Chemoradiotherapy in the treatment of cervical cancer[J].Semin Radiat,2006,16(3):177.
[18] Kantardzie N.Concurrent chemoradiation for cervical cancer:results offive randomized trials [J].Med Arh,2010,64(6):368.
[19] 魏伟锋,子宫动脉灌注新辅助化疗在II期宫颈癌治疗中的可行性及[J].临床合理用药杂志,2013,6(2):84.
[20] 熊琼英,广怡,刘成 宫颈癌新辅助化疗疗法不同途径的疗效评价[J].现代妇产科进展,2012,21(1):55-57.
[21] Gadducci A,Fabrini MG,Perrone F,et al.Pattern of failures and clinical outcome of patients with locally advanced cervical cancer treated with a tailored integrated therapeutic approach [J].Anticancer Res,2010,30(9):3731-3735.
[22] ChenH,Liang C,Zhang L,et al.Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced(stage ⅠB2 to ⅡB) cervical cancer:randomized study[J].Gynecol Oncol,2008,110(3):308-315.
[23] Watari H,Kanuma T,Ohta Y,et al.Clusterin expression inversely correlates with chemosensitivity and predicts poor survival in patients with locally advanced cervical cancer treated with cisplatin based neoadjuvant chemotherapy and radical hysterectomy [J].Pathol Oncol Res,2010,16(3):345- 352.
[24] Park JS,Jeon EK,Chun SH,et al.ERCC1(excision repair cross co mplementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer [J].Gynecol Oncol,2011,120(2):275-279.
[25] McCormack M,Ledermann JA,Hall C raggs MA,et al.A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer [J].British Journal of Cancer,2013,108(12):2464-2469.
